Addition of an extra dose of salmeterol Diskus® to conventional dose of salmeterol Diskus® in patients with COPD

Respiratory Medicine

Volumn 96, Issue 6, 2002, Pages 439-443

  Cazzola, M ^a   Santus, P ^b   Castagna, F ^b   Di Marco, F ^b   Terzano, C ^c   Matera, M G ^d   Centanni, S ^b  

^a CARDARELLI HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

COPD; Extra dose; Salmeterol

Indexed keywords

PLACEBO; SALMETEROL; BRONCHODILATING AGENT; DRUG DERIVATIVE; SALBUTAMOL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE CONTROL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DYSPNEA; FORCED EXPIRATORY VOLUME; HEADACHE; HEART PALPITATION; HEART RATE; HUMAN; METERED DOSE INHALER; NAUSEA; OXYGEN SATURATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FUNCTION; STATISTICAL SIGNIFICANCE; TREMOR; VOMITING; MIDDLE AGED; TREATMENT OUTCOME;

ALBUTEROL; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FORCED EXPIRATORY VOLUME; HUMANS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 0036591413     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.2001.1279     Document Type: Article

References (20)

1. Cazzola M, Matera MG. Should long-acting β2-agonists be considered an alternative first choice option for the treatment of stable COPD? Respir Med 1999; 93: 227-229.
2. Lötvall J. Pharmacology of bronchodilators used in the treatment of COPD. Respir Med 2000; 94 (Suppl E): S6-S10.
3. 2-agonists in the management of stable chronic obstructive pulmonary disease. Drugs 2000; 60: 307-320.
4. NHLBI/WHO. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD). NHLBI/WHO workshop report 2001.
5. Glaxo Wellcome Inc. Serevent (salmeterol xinafoate) inhalation aerosol. Product information. Glaxo Wellcome Inc. Research Triangle Park (NC), July 2000.
6. Cazzola M, Matera MG, Santangelo G, et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995; 89: 357-362.
7. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: 77S-121S.
8. American Thoracic Society. Standardization of spirometry - 1987 update. Am Rev Respir Dis 1987; 136: 1285-1298.
9. Hansen G, Andreww M, Bjermer L, et al. Retningslinjer fur utredning og behandling av kronisk obstruktiv lungesykdom. Tidsskr Nor Laegeforen 1995; 115: 710-713.
10. Lipworth BJ, Grove A. Evaluation of partial β-adrenoceptor agonist activity. Br J Clin Pharmacol 1997; 43: 9-14.
11. Cazzola M, Di Perna F, Noschese P, et al. Effects of a pre-treatment with conventional doses of formoterol, salmeterol or oxitropium bromide on the dose-response curves to salbutamol in patients suffering from partially reversible COPD. Eur Respir J 1998; 11: 1337-1341.
12. Ramirez-Venegas A, Ward J, Lentine T, et al. Salmeterol reduces dyspnoea and improves lung function in patients with COPD. Chest 1997; 112: 336-340.
13. Wolkove N, Dajczman E, Colacone A, et al. The relationship between pulmonary function and dyspnoea in obstructive lung disease. Chest 1989; 96: 1247-1251.
14. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-965.
15. Jarvis B, Markham A. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease. Drugs Aging 2001; 18: 441-472.
16. 2-agonist bronchodilators. Med Toxicol 1986; 1: 286-299.
17. Tranfa CM, Pelaia G, Germbiale RD, et al. Short-term cardiovascular effects of salmeterol. Chest 1998; 113: 1272-1276.
18. Khoukaz G, Gross NJ. Effects of salmeterol on arterial blood gases in patients with stable chronic obstructive pulmonary disease comparison with albuterol and ipratropium. Am J Respir Crit Care Med 1999; 160: 1028-1030.
19. Boyd G, Morica AH, Pounsford JC, et al. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997; 10: 815-821.
20. Lötvall J, Lunde H, Svedmyr N. Onset of bronchodilation and finger tremor induced by salmeterol and salbutamol in asthmatic patients. Can Respir J 1998; 5: 191-94.